ライフサイエンスコーパス: SLL

1 In vitro studies were performed in Mec-1 SLL cells, which express both bcl-2 messenger RNA and so

2 follows: MCL1, 38%; MCL2, 37%; IMC, 28%; and SLL, 14%.

3 her characteristics of patients with CLL and SLL differ in ways other than the absolute lymphocyte co

4 but controversy remains over whether CLL and SLL should be treated similarly.

5 and active therapeutic approach for NHL and SLL/CLL.

6 Despite complete pathologic remission at SLL after initial surgery and platinum-based chemotherap

7 lymphoma or B-small lymphocytic lymphoma (B-SLL) cell lines or patient samples.

8 imilarly analyzed low-grade (12 MALT, 16 CLL/SLL) and high-grade (19 DLCL) lymphomas.

9 A total of 33 CLL/SLL patients were enrolled; only one patient discontinue

10 HR, 2.27; 95% CI, 1.34 to 3.84) or after CLL/SLL (n=49: HR, 2.92; 95% CI, 1.66 to 5.12).

11 ving initial chemotherapy, but not after CLL/SLL (SIR: CLL/SLL = 1.13, FL = 5.96, DLBCL = 4.96; P(Dif

12 risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence r

13 Melanoma risk after CLL/SLL was significantly increased among patients who recei

14 ute to the development of melanoma after CLL/SLL.

15 s of FL (OR = 1.4, 95% CI: 1.1, 1.9) and CLL/SLL (OR = 1.5, 95% CI: 1.1, 2.0) were mainly observed am

16 e use may play a role in risks of FL and CLL/SLL in women who started use before 1980 and that increa

17 12 of 19) showed a loss of p27; MALT and CLL/SLL, however, were p27 positive.

18 d (P =.06) toward a difference between B-CLL/SLL and the lymphoplasmacytoid subtype.

19 as compared with that of patients with B-CLL/SLL, a significant difference was found (P <.

20 (Kiel classification) as a variant of B-CLL/SLL.

21 ing autoimmune diseases diagnosed before CLL/SLL (n=36: HR, 2.27; 95% CI, 1.34 to 3.84) or after CLL/

22 Among 2,126 consecutive CLL/SLL patients, 312 (15%) had ALC less than 5 x 10(9)/L.

23 from meat consumption increased risk for CLL/SLL alone.

24 LBCL and marginal zone lymphoma than for CLL/SLL and follicular lymphoma.

25 y lower rates than whites and blacks for CLL/SLL and Hodgkin lymphoma.

26 s were observed across strata of sex for CLL/SLL and marginal zone lymphoma subtypes as well as age f

27 In patients who were treated for CLL/SLL, the treatment regimen did not affect the risk of su

28 Overall response rates in CLL/SLL patients (n = 66) were 100%, 79%, and 71% in groups

29 MZL, whereas no response was observed in CLL/SLL patients.

30 sk, except for urinary tract infections (CLL/SLL), localized scleroderma, pneumonia, and gastrohepati

31 tic leukemia/small lymphocytic lymphoma (CLL/SLL) and 111 after other NHL subtypes (cumulative incide

32 tic leukemia/small lymphocytic lymphoma (CLL/SLL) but not for other NHL subtypes.

33 tic leukemia/small lymphocytic lymphoma (CLL/SLL) declined 2.1% per year.

34 tic leukemia/small lymphocytic lymphoma (CLL/SLL) was 1.66 (95% CI, 1.08-2.56; P = .02).

35 leukemia or small lymphocytic lymphoma (CLL/SLL) was the principal NHL subtype contributing to this

36 tic leukemia/small lymphocytic lymphoma (CLL/SLL).

37 tic leukemia/small lymphocytic lymphoma (CLL/SLL).

38 tic leukemia/small lymphocytic lymphoma (CLL/SLL; HR, 0.84; 95% CI, 0.31 to 2.28).

39 tic leukemia/small lymphocytic lymphoma (CLL/SLL; N = 133).

40 tic leukemia/small lymphocytic lymphoma (CLL/SLL; n = 15), mantle cell lymphoma (MCL; n = 15), low-gr

41 xpressed on tumor cells in many cases of CLL/SLL (10 of 13 cases examined) with Mig expression less f

42 of developing NHL; however, the risk of CLL/SLL appears higher than for other NHL subtypes.

43 increase NHL risk, particularly risk of CLL/SLL, and are consistent with earlier studies relating lo

44 iated with the risk of NHL, particularly CLL/SLL.

45 ansformation (RT) and 8 with progressive CLL/SLL.

46 leukemia/small lymphocytic lymphoma (RR-CLL/SLL), irrespective of risk factors associated with poor

47 hemotherapy, but not after CLL/SLL (SIR: CLL/SLL = 1.13, FL = 5.96, DLBCL = 4.96; P(Diff) < .001).

48 ved for risk of cutaneous melanoma (SIR: CLL/SLL = 1.92, FL = 1.60, DLBCL = 1.06; P(Diff) = .004).

49 BCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression

50 dent hematologic malignancies other than CLL/SLL.

51 Patients with CLL/SLL have more than twice the risk of developing a second

52 PFS time of 18.6 months in patients with CLL/SLL seems shorter than the 36- to 40-month median PFSs p

53 Of the 3,986 patients with CLL/SLL, 204 patients (5.1%) had possible RS, and 148 patien

54 he first-line treatment of patients with CLL/SLL, producing substantially higher response rates than

55 ated with other cancers in patients with CLL/SLL.

56 s (cumulative incidence by age 85 years: CLL/SLL, 1.37%; other NHL subtypes, 0.78%).

57 omas, 4 CLL/small lymphocytic lymphomas (CLL/SLLs), and 1 low-grade NHL not otherwise specified.

58 BCL, 10% (2 of 21) for FL, 55% (6 of 11) for SLL/CLL, and 11% (1/9) for MCL.

59 eficiency) mice, a new animal model of human SLL.

60 l-2 expression in a new mouse model of human SLL.

61 nterfollicular small lymphocytic lymphoma (I-SLL) has not been well characterized and its relationshi

62 d immunophenotypic features of 13 cases of I-SLL and immunoglobulin heavy chain variable (VH) gene se

63 These studies support the proposal that I-SLL represents SLL/CLL and suggest the recently proposed

64 nterestingly, the mutational status of the I-SLL VH genes seemed to correlate with the two different

65 dence of ongoing mutation, consistent with I-SLL having either a naive or memory B cell origin.

66 in MCL and IMC but only limited activity in SLL.

67 ce of disease at the second-look laparotomy (SLL) procedure after primary chemotherapy.

68 cytic leukemia/chronic lymphocytic leukemia (SLL/CLL).

69 released into the seminiferous lobule lumen (SLL), where they develop into spermatozoa without direct

70 IMC), and small B-cell lymphocytic lymphoma (SLL) are B-cell malignancies that express CD20 and are i

71 ukemia (CLL) and small lymphocytic lymphoma (SLL) are currently considered the same entity, but contr

72 relationship to small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) is uncertain.

73 d MCL, three had small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL), and two had

74 nced for the CLL/small lymphocytic lymphoma (SLL) subtype (OR: 1.0; 3.2 [0.7-15.7]; 14.1 [1.9-103.2];

75 c leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at 24 hours.

76 efractory CLL or small lymphocytic lymphoma (SLL) to assess safety, pharmacokinetic profile, and effi

77 c leukemia (CLL)/small lymphocytic lymphoma (SLL) who presented at The University of Texas M.D. Ander

78 eukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse

79 a (NHL), such as small lymphocytic lymphoma (SLL), and many other cancers.

80 atients with CLL/small lymphocytic lymphoma (SLL), prolymphocytic leukemia, or Richter's transformati

81 of patients with small lymphocytic lymphoma (SLL)/B-cell chronic lymphocytic leukemia (B-CLL) treated

82 ttle activity in small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) and to be associ

83 ormed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one

84 ncluded 1 of 45 small lymphocytic lymphomas (SLLs), 2 of 38 follicular small cleaved-cell lymphomas (

85 trial, 202 eligible patients with a negative SLL were randomly selected to receive either 15 mCi IP 3

86 I epithelial ovarian cancer after a negative SLL.

87 tumor recurrence within 5 years of negative SLL.

88 d in five cadaveric wrists that had a normal SLL proved with dissection.

89 14 patients with an arthroscopically normal SLL and in five cadaveric wrists that had a normal SLL p

90 ame CD5-positive B cell phenotype typical of SLL or CLL.

91 our of 21 assessable patients responded (one SLL patient had a CR, one FL patient had a CR unconfirme

92 Patients with CLL or SLL can be treated similarly.

93 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody

94 electronic database for patients with CLL or SLL who presented to The University of Texas M.D. Anders

95 l responses in patients with relapsed CLL or SLL, including those with poor prognostic features.

96 mong patients with previously treated CLL or SLL.

97 Although L and N at the -2 position (-SLL, -ANL) do not conform to the SKL motif, both functio

98 s support the proposal that I-SLL represents SLL/CLL and suggest the recently proposed two types of C

99 ion of flatfish spermatids isolated from the SLL with rLh specifically promotes their differentiation

100 und to the Lhcgrba of free spermatids in the SLL, showing that circulating gonadotropin can reach the

101 he volar, middle, and dorsal portions of the SLL can be differentiated on the basis of MR appearance

102 he volar, middle, and dorsal portions of the SLL in 14 patients with an arthroscopically normal SLL a

103 The trapezoidal volar portion of the SLL was seen with inhomogeneous high intermediate signal

104 Patients with SLL or CLL have yet to respond.